17 results on '"C. Woischke"'
Search Results
2. PD-0066: A 24-miRNA signature predicting HPV status in head and neck cancer
- Author
-
Daniel Zips, P. Weber, Claus Rödel, Michael Henke, Martin Werner, M. Krause, Annett Linge, Jürgen Debus, Lars Schüttrumpf, Stephanie E. Combs, Philipp Baumeister, Kristian Unger, J. Heß, Henning Schäfer, Cornelius Maihoefer, H. Zitzelsberger, T. Heider, Axel Walch, U. Ganswindt, B. Michael, Martin Stuschke, C. Woischke, S. Marschner, Claus Belka, and Inge Tinhofer
- Subjects
Oncology ,Mirna signature ,medicine.medical_specialty ,business.industry ,Internal medicine ,Head and neck cancer ,medicine ,Radiology, Nuclear Medicine and imaging ,Hematology ,medicine.disease ,business ,Hpv status - Published
- 2020
- Full Text
- View/download PDF
3. Identification of a gene expression signature associated with brain metastasis in colorectal cancer.
- Author
-
Michl M, Taverna F, Woischke C, Li P, Klauschen F, Kirchner T, Heinemann V, von Bergwelt-Baildon M, Stahler A, Herold TM, Jurinovic V, Engel J, Kumbrink J, and Neumann J
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Transcriptome, Liver Neoplasms secondary, Liver Neoplasms genetics, Liver Neoplasms metabolism, Prognosis, Gene Expression Profiling, ROC Curve, Adult, Gene Expression Regulation, Neoplastic, Brain Neoplasms secondary, Brain Neoplasms genetics, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism
- Abstract
Purpose: Brain metastasis (BM) in colorectal cancer (CRC) is a rare event with poor prognosis. Apart from (K)RAS status and lung and bone metastasis no biomarkers exist to identify patients at risk. This study aimed to identify a gene expression signature associated with colorectal BM., Methods: Three patient groups were formed: 1. CRC with brain metastasis (BRA), 2. exclusive liver metastasis (HEP) and, 3. non-metastatic disease (M0). RNA was extracted from primary tumors and mRNA expression was measured using a NanoString Panel (770 genes). Expression was confirmed by qPCR in a validation cohort. Statistical analyses including multivariate logistic regression followed by receiver operating characteristic (ROC) analysis were performed., Results: EMILIN3, MTA1, SV2B, TMPRSS6, ACVR1C, NFAT5 and SMC3 were differentially expressed in BRA and HEP/M0 groups. In the validation cohort, differential NFAT5, ACVR1C and SMC3 expressions were confirmed. BRA patients showed highest NFAT5 levels compared to HEP/M0 groups (global p = 0.02). High ACVR1C expression was observed more frequently in the BRA group (42.9%) than in HEP (0%) and M0 (7.1%) groups (global p = 0.01). High SMC3 expressions were only detectable in the BRA group (global p = 0.003). Only patients with BM showed a combined high expression of NFAT5, ACVR1C or SMC3 as well as of all three genes. ROC analysis revealed a good prediction of brain metastasis by the three genes (area under the curve (AUC) = 0.78)., Conclusions: The NFAT5, ACVR1C and SMC3 gene expression signature is associated with colorectal BM. Future studies should further investigate the importance of this biomarker signature., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil.
- Author
-
Schöckel L, Woischke C, Surendran SA, Michl M, Schiergens T, Hölscher A, Glass F, Kreissl P, Klauschen F, Günther M, Ormanns S, and Neumann J
- Subjects
- Humans, Fluorouracil pharmacology, Fluorouracil therapeutic use, PPAR gamma agonists, Case-Control Studies, Cell Line, Tumor, Cell Proliferation, Drug Resistance, Neoplasm, Gene Expression Regulation, Neoplastic, Diabetes Mellitus, Type 2 drug therapy, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology
- Abstract
Background: Peroxisome proliferator-activated receptor gamma (PPARG) is a member of the nuclear receptor family. It is involved in the regulation of adipogenesis, lipid metabolism, insulin sensitivity, vascular homeostasis and inflammation. In addition, PPARG agonists, known as thiazolidinediones, are well established in the treatment of type 2 diabetes mellitus. PPARGs role in cancer is a matter of debate, as pro- and anti-tumour properties have been described in various tumour entities. Currently, the specific role of PPARG in patients with colorectal cancer (CRC) is not fully understood., Material and Methods: The prognostic impact of PPARG expression was investigated by immunohistochemistry in a case-control study using a matched pair selection of CRC tumours (n = 246) with either distant metastases to the liver (n = 82), lung (n = 82) or without distant metastases (n = 82). Its effect on proliferation as well as the sensitivity to the chemotherapeutic drug 5-fluorouracil (5-FU) was examined after activation, inhibition, and transient gene knockdown of PPARG in the CRC cell lines SW403 and HT29., Results: High PPARG expression was significantly associated with pulmonary metastasis (p = 0.019). Patients without distant metastases had a significantly longer overall survival with low PPARG expression in their tumours compared to patients with high PPARG expression (p = 0.045). In the pulmonary metastasis cohort instead, a trend towards longer survival was observed for patients with high PPARG expression in their tumour (p = 0.059). Activation of PPARG by pioglitazone and rosiglitazone resulted in a significant dose-dependent increase in proliferation of CRC cell lines. Inhibition of PPARG by its specific inhibitor GW9662 and siRNA-mediated knockdown of PPARG significantly decreased proliferation. Activating PPARG significantly increased the CRC cell lines sensitivity to 5-FU while its inhibition decreased it., Conclusion: The prognostic effect of PPARG expression depends on the metastasis localization in advanced CRC patients. Activation of PPARG increased malignancy associated traits such as proliferation in CRC cell lines but also increases sensitivity towards the chemotherapeutic agent 5-FU. Based on this finding, a combination therapy of PPARG agonists and 5-FU-based chemotherapy constitutes a promising strategy which should be further investigated., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. [Molecular pathology of colorectal cancer].
- Author
-
Woischke C, Michl M, and Neumann J
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Pathology, Molecular, Biomarkers, Colorectal Neoplasms diagnosis
- Abstract
In recent years, the treatment of colorectal carcinoma has experienced increasing individualization. In addition to RAS and BRAF mutational status that is firmly established in routine diagnostics, new therapeutic options evolved based on MSI and HER2 status as well as primary tumour localization. Offering the best targeted options in therapy requires new evidence-based decision-making algorithms regarding timing and scope of molecular pathological diagnostics in order for patients to receive an optimized therapy according to current treatment guidelines. New targeted therapies, some of which are about to be approved and for which pathology has to provide new molecular pathological biomarkers, will also play an increasingly important role in the future., (© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
6. PBXIP1 - An indicator for poor outcome and metastatic spread in colorectal cancer.
- Author
-
Ilmer M, Renz BW, Kühn F, Drefs M, Koliogiannis D, Werner J, Kirchner T, Horst D, and Woischke C
- Subjects
- Cell Line, Tumor, Co-Repressor Proteins genetics, Epithelial-Mesenchymal Transition genetics, Gene Expression Regulation, Neoplastic, Humans, Prognosis, Transcription Factors metabolism, Tumor Microenvironment, Colonic Neoplasms genetics, Colorectal Neoplasms pathology
- Abstract
Tumor cell heterogeneity in colorectal cancers within the same genetic background is a well-described phenomenon. In this work, we investigate the role of hematopoietic pre-B-cell leukemia transcription factor (PBX)-interacting protein (HPIP/PBXIP1) in tumor cell subpopulations with differential Wingless-related integration site (WNT) activity as well as its potential associations with epithelial-mesenchymal transition (EMT) and clinical associations in colorectal cancer. We used in situ analyses to identify immunohistochemical expression of PBXIP1 in normal and colorectal cancer tissues and biostatistical approaches to determine its function and regulatory correlations. Clinical associations were analyzed in a case control collection of metastatic and non-metastatic colon cancers and gene expression data sets of colorectal cancers with recorded clinical follow-up data. PBXIP1 was expressed in single epithelial cells from tumor-free colon crypts as well as in tumor cells with high WNT activity. Colorectal cancer cells close to the invasive edge seemed to possess higher PBXIP1 levels indicative of associations with EMT, whereas stromal cells in the tumor microenvironment appeared mostly negative. PBXIP1 expression was associated with local metastasis to lymph nodes as well as distant metastasis to secondary organs in a case-control collection consisting of 91 cases with or without distant metastasis. Furthermore, high expression of PBXIP1 in The Cancer Genome Atlas (TCGA) data set was associated with worse overall survival in colon cancer. PBXIP1 might serve as a novel histological prognostic and regulatory indicator for EMT processes in colorectal cancer that seems to correlate with cancer cell subtypes of high baseline WNT activity., (Copyright © 2022 Elsevier GmbH. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
7. Integration of p16/HPV DNA Status with a 24-miRNA-Defined Molecular Phenotype Improves Clinically Relevant Stratification of Head and Neck Cancer Patients.
- Author
-
Hess J, Unger K, Maihoefer C, Schüttrumpf L, Weber P, Marschner S, Wintergerst L, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Sörensen K, Baumann M, Tinhofer I, Combs SE, Debus J, Schäfer H, Krause M, Linge A, von der Grün J, Stuschke M, Zips D, Canis M, Lauber K, Ganswindt U, Henke M, Zitzelsberger H, and Belka C
- Abstract
Human papillomavirus (HPV)-driven head and neck squamous cell carcinomas (HNSCC) generally have a more favourable prognosis. We hypothesized that HPV-associated HNSCC may be identified by an miRNA-signature according to their specific molecular pathogenesis, and be characterized by a unique transcriptome compared to HPV-negative HNSCC. We performed miRNA expression profiling of two p16/HPV DNA characterized HNSCC cohorts of patients treated by adjuvant radio(chemo)therapy (multicentre DKTK-ROG n = 128, single-centre LMU-KKG n = 101). A linear model predicting HPV status built in DKTK-ROG using lasso-regression was tested in LMU-KKG. LMU-KKG tumours ( n = 30) were transcriptome profiled for differential gene expression and miRNA-integration. A 24-miRNA signature predicted HPV-status with 94.53% accuracy (AUC: 0.99) in DKTK-ROG, and 86.14% (AUC: 0.86) in LMU-KKG. The prognostic values of 24-miRNA- and p16/HPV DNA status were comparable. Combining p16/HPV DNA and 24-miRNA status allowed patient sub-stratification and identification of an HPV-associated patient subgroup with impaired overall survival. HPV-positive tumours showed downregulated MAPK , Estrogen , EGFR , TGFbeta , WNT signaling activity. miRNA-mRNA integration revealed HPV-specific signaling pathway regulation, including PD-L1 expression/PD-1 checkpoint pathway in cancer in HPV-associated HNSCC. Integration of clinically established p16/HPV DNA with 24-miRNA signature status improved clinically relevant risk stratification, which might be considered for future clinical decision-making with respect to treatment de-escalation in HPV-associated HNSCC.
- Published
- 2022
- Full Text
- View/download PDF
8. Novel predictors for liver transplantation or death in drug-induced acute liver failure.
- Author
-
Weber S, Woischke C, Denk G, and Gerbes AL
- Subjects
- Biomarkers, Humans, Prospective Studies, Severity of Illness Index, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, End Stage Liver Disease complications, End Stage Liver Disease diagnosis, End Stage Liver Disease surgery, Liver Failure, Acute chemically induced, Liver Failure, Acute diagnosis, Liver Failure, Acute surgery, Liver Transplantation adverse effects
- Abstract
Objective: Drug-induced liver injury (DILI) is a leading cause of acute liver failure (ALF). Predictors for orthotopic liver transplantation (OLT) or death in drug-induced ALF (DI-ALF) are scarce., Methods: In total 33 of 346 patients recruited for our prospective study on potentially hepatotoxic drugs had ALF. DILI diagnosis was based on Roussel Uclaf Causality Assessment Method (RUCAM) score and expert opinion. Area under the receiver operating characteristic (AUROC) curve, Youden's index and positive and negative likelihood ratios were calculated to identify the best performing predictive markers and scores for OLT or death., Results: Poor outcome was associated with lower baseline platelet counts and cholinesterase (CHE) levels, higher International Normalized Ratio (INR) levels and Model for End-Stage Liver Disease (MELD) scores. Yet, AUROC reached a maximum of only 0.71-0.75 for either of those laboratory markers or the MELD score. Notably however, combinations of those scores were highly discriminatory, in particular INR/(CHE*platelet count) and MELD/(CHE*platelet count), showing an AUROC of 0.91, a positive likelihood ratios of 13.78 and a negative likelihood ratios of 0.08., Conclusion: While baseline MELD score, INR, CHE, and platelet counts had limited potential to discriminate between DI-ALF with survival or poor outcome, their combinations were highly associated with OLT or death in patients with DI-ALF., (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
9. Rapid prototyping vaccine approach in mice against multi-drug resistant Gram-negative organisms from clinical isolates based on outer membrane vesicles.
- Author
-
Pritsch M, Ben Khaled N, Liegl G, Schubert S, Hoelscher M, Woischke C, Arens N, Thorn-Seshold J, Kammermeier S, and Wieser A
- Subjects
- Adjuvants, Immunologic, Animals, Antibodies, Bacterial, Extracellular Vesicles immunology, Extracellular Vesicles microbiology, Gram-Negative Bacteria, Humans, Immunity, Humoral, Mice, Mice, Inbred BALB C, Vaccination, Bacterial Outer Membrane Proteins immunology, Bacterial Vaccines, Drug Resistance, Multiple, Bacterial, Gram-Negative Bacterial Infections prevention & control
- Abstract
Hospital-acquired infections due to multi-drug resistant Gram-negative organisms (MDRGNO) pose a major threat to global health. A vaccine preventing colonization and consecutive infection with MDRGNO could be particularly valuable, as therapeutic options become increasingly limited. Outer membrane vesicles (OMV) of Escherichia coli strain CFT073 as well as three MDRGNO strains that had caused severe infections in humans were administered intranasally to mice, with and without cholera toxin as an adjuvant. The humoral immune responses were comparatively matched with the sera of patients, who had suffered an infection caused by the respective bacterium. Additionally, systemic and local toxicity was evaluated. Intranasal vaccination with OMV could elicit solid humoral immune responses (total IgM and IgG), specific for the respective MDRGNO in mice; decoration of vital bacterial membranes with antibodies was comparable to patients who had survived systemic infection with the respective bacterial isolate. After intranasal vaccination of mice with OMV no signs of local or systemic toxicity were observed. Intranasal vaccination with OMV may open up a rapid vaccine approach to prevent colonization and/or infection with pathogenic MDRGNOs, especially in an outbreak setting within a hospital. It may also be an option for patients who have to undergo elective interventions in centers with a high risk of infection for certain common MDRGNO. Future studies need to include challenge experiments as well as phase I trials in humans., (© 2021 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
10. Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
- Author
-
Woischke C, Jung P, Jung A, Kumbrink J, Eisenlohr S, Auernhammer CJ, Vieth M, Kirchner T, and Neumann J
- Subjects
- Biomarkers, Tumor analysis, Carcinoma, Large Cell chemistry, Carcinoma, Large Cell pathology, Carcinoma, Large Cell therapy, Carcinoma, Neuroendocrine chemistry, Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine therapy, Carcinoma, Squamous Cell chemistry, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell therapy, Colonic Neoplasms chemistry, Colonic Neoplasms pathology, Colonic Neoplasms therapy, Fatal Outcome, Female, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Neoplasms, Complex and Mixed chemistry, Neoplasms, Complex and Mixed pathology, Neoplasms, Complex and Mixed therapy, Phenotype, Treatment Outcome, Biomarkers, Tumor genetics, Carcinoma, Large Cell genetics, Carcinoma, Neuroendocrine genetics, Carcinoma, Squamous Cell genetics, Colonic Neoplasms genetics, F-Box-WD Repeat-Containing Protein 7 genetics, Mutation, Neoplasms, Complex and Mixed genetics
- Abstract
We present two rare cases of mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon. A literature search revealed only three published cases with similar histology but none of these reports provided profound molecular and mutational analyses. Our two cases exhibited a distinct, colon-like immunophenotype with strong nuclear CDX2 and β-catenin expression in more than 90% of the tumour cells of both components. We analysed the two carcinomas regarding microsatellite stability, RAS, BRAF and PD-L1 status. In addition, next-generation panel sequencing with Ion AmpliSeq™ Cancer Hotspot Panel v2 was performed. This approach revealed mutations in FBXW7, CTNNB1 and PIK3CA in the first case and FBXW7 and RB1 mutations in the second case. We looked for similar mutational patterns in three publicly available colorectal adenocarcinoma data sets, as well as in collections of colorectal mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) and colorectal neuroendocrine carcinomas. This approach indicated that the FBXW7 point mutation, without being accompanied by classical adenoma-carcinoma sequence mutations, such as APC, KRAS and TP53, likely occurs at a relatively high frequency in mixed neuroendocrine and squamous cell carcinoma and therefore may be characteristic for this rare tumour type. FBXW7 codifies the substrate recognition element of an ubiquitin ligase, and inactivating FBXW7 mutations lead to an exceptional accumulation of its target β-catenin which results in overactivation of the Wnt-signalling pathway. In line with previously described hypotheses of de-differentiation of colon cells by enhanced Wnt-signalling, our data indicate a crucial role for mutant FBXW7 in the unusual morphological switch that determines these rare neoplasms. Therefore, mixed large cell neuroendocrine and a squamous cell carcinoma can be considered as a distinct carcinoma entity in the colon, defined by morphology, immunophenotype and distinct molecular genetic alteration(s)., (© 2020 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland & John Wiley & Sons, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
11. A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.
- Author
-
Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger H, Ganswindt U, Henke M, and Belka C
- Subjects
- Adult, Aged, Aged, 80 and over, Area Under Curve, Female, Head and Neck Neoplasms pathology, Head and Neck Neoplasms therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Grading, Neoplasm Staging, Papillomaviridae, Papillomavirus Infections complications, Prognosis, Proportional Hazards Models, Treatment Outcome, Biomarkers, Tumor, Head and Neck Neoplasms etiology, Head and Neck Neoplasms mortality, MicroRNAs genetics, Transcriptome
- Abstract
Purpose: Human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) is associated with unfavorable prognosis, while independent prognostic markers remain to be defined., Experimental Design: We retrospectively performed miRNA expression profiling. Patients were operated for locally advanced HPV-negative HNSCC and had received radiochemotherapy in eight different hospitals (DKTK-ROG; n = 85). Selection fulfilled comparable demographic, treatment, and follow-up characteristics. Findings were validated in an independent single-center patient sample (LMU-KKG; n = 77). A prognostic miRNA signature was developed for freedom from recurrence and tested for other endpoints. Recursive-partitioning analysis was performed on the miRNA signature, tumor and nodal stage, and extracapsular nodal spread. Technical validation used qRT-PCR. An miRNA-mRNA target network was generated and analyzed., Results: For DKTK-ROG and LMU-KKG patients, the median follow-up was 5.1 and 5.3 years, and the 5-year freedom from recurrence rate was 63.5% and 75.3%, respectively. A five-miRNA signature (hsa-let-7g-3p, hsa-miR-6508-5p, hsa-miR-210-5p, hsa-miR-4306, and hsa-miR-7161-3p) predicted freedom from recurrence in DKTK-ROG [hazard ratio (HR) 4.42; 95% confidence interval (CI), 1.98-9.88, P < 0.001], which was confirmed in LMU-KKG (HR 4.24; 95% CI, 1.40-12.81, P = 0.005). The signature also predicted overall survival (HR 3.03; 95% CI, 1.50-6.12, P = 0.001), recurrence-free survival (HR 3.16; 95% CI, 1.65-6.04, P < 0.001), and disease-specific survival (HR 5.12; 95% CI, 1.88-13.92, P < 0.001), all confirmed in LMU-KKG data. Adjustment for relevant covariates maintained the miRNA signature predicting all endpoints. Recursive-partitioning analysis of both samples combined classified patients into low ( n = 17), low-intermediate ( n = 80), high-intermediate ( n = 48), or high risk ( n = 17) for recurrence ( P < 0.001)., Conclusions: The five-miRNA signature is a strong and independent prognostic factor for disease recurrence and survival of patients with HPV-negative HNSCC. See related commentary by Clump et al., p. 1441 ., (©2018 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
12. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
- Author
-
Wintergerst L, Selmansberger M, Maihoefer C, Schüttrumpf L, Walch A, Wilke C, Pitea A, Woischke C, Baumeister P, Kirchner T, Belka C, Ganswindt U, Zitzelsberger H, Unger K, and Hess J
- Subjects
- Female, Gene Dosage, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Head and Neck Neoplasms drug therapy, Head and Neck Neoplasms radiotherapy, Humans, Male, Middle Aged, Prognosis, Squamous Cell Carcinoma of Head and Neck drug therapy, Squamous Cell Carcinoma of Head and Neck radiotherapy, Chromosomes, Human, Pair 16 genetics, Head and Neck Neoplasms diagnosis, Head and Neck Neoplasms genetics, RNA, Messenger genetics, Squamous Cell Carcinoma of Head and Neck diagnosis, Squamous Cell Carcinoma of Head and Neck genetics, Transcriptome
- Abstract
Previously, we have shown that copy number gain of the chromosomal band 16q24.3 is associated with impaired clinical outcome of radiotherapy-treated head and neck squamous cell carcinoma (HNSCC) patients. We set out to identify a prognostic mRNA signature from genes located on 16q24.3 in radio(chemo)therapy-treated HNSCC patients of the TCGA (The Cancer Genome Atlas, n = 99) cohort. We applied stepwise forward selection using expression data of 41 16q24.3 genes. The resulting optimal Cox-proportional hazards regression model included the genes APRT, CENPBD1, CHMP1A, and GALNS. Afterward, the prognostic value of the classifier was confirmed in an independent cohort of HNSCC patients treated by adjuvant radio(chemo)therapy (LMU-KKG cohort). The signature significantly differentiated high- and low-risk patients with regard to overall survival (HR = 2.01, 95% CI 1.10-3.70; P = 0.02125), recurrence-free survival (HR = 1.84, 95% CI 1.01-3.34; P = 0.04206), and locoregional recurrence-free survival (HR = 1.87, 95% CI 1.03-3.40; P = 0.03641). The functional impact of the four signature genes was investigated after reconstruction of a gene association network from transcriptome data of the TCGA HNSCC cohort using a partial correlation approach. Subsequent pathway enrichment analysis of the network neighborhood (first and second) of the signature genes suggests involvement of HNSCC-associated signaling pathways such as apoptosis, cell cycle, cell adhesion, EGFR, JAK-STAT, and mTOR. Furthermore, a detailed analysis of the first neighborhood revealed a cluster of co-expressed genes located on chromosome 16q, substantiating the impact of 16q24.3 alterations in poor clinical outcome of HNSCC. The reported gene expression signature represents a prognostic marker in HNSCC patients following postoperative radio(chemo)therapy., (© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
13. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
- Author
-
Maihoefer C, Schüttrumpf L, Macht C, Pflugradt U, Hess J, Schneider L, Woischke C, Walch A, Baumeister P, Kirchner T, Zitzelsberger H, Belka C, and Ganswindt U
- Subjects
- Adult, Aged, Aged, 80 and over, Cisplatin administration & dosage, Combined Modality Therapy, Epithelial Cells, Female, Fluorouracil administration & dosage, Germany, Head and Neck Neoplasms therapy, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Postoperative Care, Prospective Studies, Retrospective Studies, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell therapy, Chemoradiotherapy, Laryngeal Neoplasms therapy, Mouth Neoplasms therapy, Pharyngeal Neoplasms therapy
- Abstract
Background: Postoperative (chemo) radiation improves tumor control and survival in high-risk patients with head and neck squamous cell carcinoma based on established risk factors. The clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer" focuses on the identification and validation of new biomarkers, which are aimed at eventually stratifying and personalizing the therapy concept. Hence, we reviewed all patients with head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, treated with postoperative (chemo) radiation from 06/2008 until 06/2015 at the Department of Radiation Oncology in the University Hospital, LMU Munich. Here we report the clinical results of the cohort, laying the foundation for further research within the framework of a clinical cooperation group., Methods: Patient data were retrospectively (until 2013) and prospectively (from 2013) collected and analyzed for outcome and treatment failures with regard to previously described and established risk factors., Results: We identified 302 patients (median follow-up 45 months, average age 60.7 years), having received postoperative (chemo)radiation (median 64 Gy). Chemotherapy was added in 58% of cases, mostly Cisplatin/5- Fluorouracil in concordance with the ARO 96-3 study. The 3-year overall survival, local, locoregional and distant failure estimates were 70.5, 9.7, 12.2 and 13.5%, respectively. Human papillomavirus-associated oropharyngeal cancer was associated with a significant improved overall survival, locoregional, distant and overall tumor control rates in multivariate analysis. Additionally, in multivariate analysis, for local failure, resection status and perineural invasion, for locoregional and distant failure extracapsular extension and for overall survival the presence of nodal disease were significant adverse factors. Moreover, 138 patients have been treated in concordance with the ARO 96-3 protocol, corroborating the results of this study., Conclusions: Our cohort represents a large unselected cohort of patients with head and neck squamous cell carcinoma treated with postoperative (chemo)radiation. Tumor control rates and survival rates are consistent with the results of previously reported data.
- Published
- 2018
- Full Text
- View/download PDF
14. Qualitative and Quantitative Imaging Evaluation of Renal Cell Carcinoma Subtypes with Grating-based X-ray Phase-contrast CT.
- Author
-
Braunagel M, Birnbacher L, Willner M, Marschner M, De Marco F, Viermetz M, Notohamiprodjo S, Hellbach K, Auweter S, Link V, Woischke C, Reiser MF, Pfeiffer F, Notohamiprodjo M, and Herzen J
- Subjects
- Antigens, Neoplasm, Humans, Mitogen-Activated Protein Kinases, Sensitivity and Specificity, Carcinoma, Renal Cell diagnostic imaging, Carcinoma, Renal Cell pathology, Kidney Neoplasms diagnostic imaging, Kidney Neoplasms pathology, Tomography, X-Ray Computed methods
- Abstract
Current clinical imaging methods face limitations in the detection and correct characterization of different subtypes of renal cell carcinoma (RCC), while these are important for therapy and prognosis. The present study evaluates the potential of grating-based X-ray phase-contrast computed tomography (gbPC-CT) for visualization and characterization of human RCC subtypes. The imaging results for 23 ex vivo formalin-fixed human kidney specimens obtained with phase-contrast CT were compared to the results of the absorption-based CT (gbCT), clinical CT and a 3T MRI and validated using histology. Regions of interest were placed on each specimen for quantitative evaluation. Qualitative and quantitative gbPC-CT imaging could significantly discriminate between normal kidney cortex (54 ± 4 HUp) and clear cell (42 ± 10), papillary (43 ± 6) and chromophobe RCCs (39 ± 7), p < 0.05 respectively. The sensitivity for detection of tumor areas was 100%, 50% and 40% for gbPC-CT, gbCT and clinical CT, respectively. RCC architecture like fibrous strands, pseudocapsules, necrosis or hyalinization was depicted clearly in gbPC-CT and was not equally well visualized in gbCT, clinical CT and MRI. The results show that gbPC-CT enables improved discrimination of normal kidney parenchyma and tumorous tissues as well as different soft-tissue components of RCCs without the use of contrast media.
- Published
- 2017
- Full Text
- View/download PDF
15. In-depth mutational analyses of colorectal neuroendocrine carcinomas with adenoma or adenocarcinoma components.
- Author
-
Woischke C, Schaaf CW, Yang HM, Vieth M, Veits L, Geddert H, Märkl B, Stömmer P, Schaeffer DF, Frölich M, Blum H, Vosberg S, Greif PA, Jung A, Kirchner T, and Horst D
- Subjects
- Adenocarcinoma pathology, Adenoma pathology, Adenomatous Polyposis Coli Protein genetics, Aged, Aged, 80 and over, Alleles, Carcinoma, Neuroendocrine pathology, Colorectal Neoplasms pathology, DNA Mutational Analysis, Female, Gene Frequency, Humans, Male, Middle Aged, Mutation, Proto-Oncogene Proteins p21(ras) genetics, Tumor Suppressor Protein p53 genetics, Exome Sequencing, Adenocarcinoma genetics, Adenoma genetics, Carcinoma, Neuroendocrine genetics, Colorectal Neoplasms genetics
- Abstract
Neuroendocrine carcinomas (NECs) of the colorectum are rare but highly aggressive neoplasms. These tumors show some shared genetic alterations with colorectal adenocarcinomas, and most of them have adjacent glandular adenoma or adenocarcinoma components. However, genetic data on colorectal NECs still are sparse and insufficient for definite conclusions regarding their molecular origin. Based on morphological characterization, panel and whole-exome sequencing, we here present results from an in-depth analysis of a collection of 15 colorectal NECs with glandular components, 10 of which by definition were mixed adenoneuroendocrine carcinomas (MANECs). Among shared genetic alterations of both tumor components, we most frequently found TP53, KRAS and APC mutations that also had highest allele frequencies. Mutations exclusive to glandular or neuroendocrine components outnumbered shared mutations but occurred at lower allele frequencies. Our findings not only provide additional evidence for a common clonal origin of colorectal NECs and adjacent glandular tumor components, but strongly suggest their development through the classical adenoma-carcinoma sequence. Moreover, our data imply early separation of glandular and neuroendocrine components during malignant transformation with subsequent independent mutational evolution.
- Published
- 2017
- Full Text
- View/download PDF
16. CYB5R1 links epithelial-mesenchymal transition and poor prognosis in colorectal cancer.
- Author
-
Woischke C, Blaj C, Schmidt EM, Lamprecht S, Engel J, Hermeking H, Kirchner T, and Horst D
- Subjects
- Aged, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Cell Line, Tumor, Colonic Neoplasms metabolism, Colonic Neoplasms surgery, Cytochrome-B(5) Reductase metabolism, Female, Humans, Kaplan-Meier Estimate, Male, Multivariate Analysis, Prognosis, RNA Interference, Treatment Outcome, Colonic Neoplasms genetics, Cytochrome-B(5) Reductase genetics, Epithelial-Mesenchymal Transition genetics, Gene Expression Regulation, Neoplastic
- Abstract
Colorectal cancers show significant tumor cell heterogeneity within the same core genetic background. Epithelial-mesenchymal transition (EMT) is an important functional aspect of this heterogeneity and hallmark of colorectal cancer progression. Here, we identify CYB5R1, an enzyme involved in oxidative stress protection and drug metabolism, as an indicator of EMT in colon cancer. We demonstrate high CYB5R1 expression in colorectal cancer cells undergoing EMT at the infiltrative tumor edge and reveal an extraordinarily strong association of CYB5R1 expression with two core EMT gene expression signatures in a large independent colon cancer data set from The Cancer Genome Atlas (TCGA). Furthermore, we demonstrate that CYB5R1 is required for an infiltrative tumor cell phenotype, and robustly linked with poor prognosis in colorectal cancer. Our findings have important implications for colon cancer cells undergoing EMT and may be exploited for diagnostic and therapeutic purposes., Competing Interests: No conflicts of interest.
- Published
- 2016
- Full Text
- View/download PDF
17. Helicobacter pylori interferes with leukocyte migration via the outer membrane protein HopQ and via CagA translocation.
- Author
-
Busch B, Weimer R, Woischke C, Fischer W, and Haas R
- Subjects
- Cells, Cultured, Helicobacter pylori immunology, Host-Pathogen Interactions, Humans, Immunologic Factors metabolism, Leukocytes physiology, Antigens, Bacterial metabolism, Bacterial Outer Membrane Proteins metabolism, Bacterial Proteins metabolism, Cell Movement drug effects, Helicobacter pylori physiology, Leukocytes immunology, Leukocytes microbiology, Virulence Factors metabolism
- Abstract
The human gastric pathogen Helicobacter pylori is a paradigm for chronic bacterial infections. Persistent colonization of the stomach mucosa is facilitated by several mechanisms of immune evasion and immune modulation, such as avoidance of Toll-like receptor recognition or skewing of effector T cell responses. Interactions of H. pylori with different immune cells have been described with respect to immune cell activation, cytokine release, or oxidative burst induction. We show here that H. pylori infection of human granulocytes, or of HL-60 cells differentiated to a granulocyte-like phenotype (dHL-60 cells) results in inhibition of cell migration under different conditions. Migration of dHL-60 cells in a three-dimensional collagen gel was found to be inhibited independently of the cag pathogenicity island, whereas migration inhibition in an under agarose assay was dependent on the cag pathogenicity island, on its effector protein CagA, and on the outer membrane protein HopQ. CagA translocation into leukocytes is accompanied by its tyrosine phosphorylation and by proteolytic processing into an N-terminal 100 kDa and a C-terminal 35 kDa fragment at a distinct cleavage site. By using complemented H. pylori strains producing either phosphorylation-resistant or cleavage-resistant CagA variants, we show that CagA tyrosine phosphorylation is required for migration inhibition, but CagA processing is not. Our results suggest that direct contact of H. pylori with immune cells subverts not only their activation characteristics, but also their migratory behaviour., (Copyright © 2015 Elsevier GmbH. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.